Wilson Wolf was established in 1998 to pioneer the development of innovative mammalian cell culture devices. They have created cell culture devices for a wide variety of applications including monoclonal antibody production, living skin, corneal storage, islet transplants for type 1 diabetes, immunotherapy, and routine cell culture. Wilson Wolf is dedicated to helping scientists and businesses advance the field of healthcare through the use of their revolutionary gas-permeable cell culture device platform.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. It offers DEL screening and library customization, chemical synthesis, and new drug research and development project transfer services. The company was founded by Jin Li on February 22, 2012 and is headquartered in Chengdu, China.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter referred to as “BlissBio”), founded in Qiantang Area, Hangzhou, Zhejiang Province in December 2017 by a number of American PhDs, is a clinical-stage national high-tech biopharmaceutical enterprise with independent intellectual properties that focuses on R&D and commercialization of anti-tumor macromolecular biotherapeutics. Since its foundation, guided by unmet clinical needs and based on rich experience accumulated in industrial R&D full life cycle of new medications, centering around multiple oncology indications, with continuous development and layout of gradient product pipeline of differentiated macromolecular biological innovative drugs, and through independent R&D and external cooperation as well, BlissBio has established and improved its multi-tech platforms, as well as independent capacity of production of antibody and ADC that meet international GMP standards. With “Together, We Improve Human Health” as the core value, through multi-level collaborations and developments, BlissBio will continue to focus on innovative drugs to benefit patients as soon as possible.

Hypros is the world's leading high-tech enterprise in precision medical and genetic big data. The company is committed to integrating cutting-edge emerging technologies such as liquid biopsy, gene sequencing, artificial intelligence, and big data. It focuses on the whole process of diagnosis and treatment of cancer patients, and is determined to use technology to improve the quality of life and make every life healthy for 120 years. Hypros has completed the multi-center globalization of Shenzhen R&D Headquarters, Third-Party Medical Laboratory, GMP Production Workshop, US R&D Center, Hypus Genome Center and Shangrao International Precision Medical Health Industrial Park. The company invested hundreds of millions of dollars to introduce the world's most advanced Illumina NovaSeq6000, HiSeq X Ten, NextSeq500/550 series sequencing platform and digital PCR platform, successfully built the world's top genetic testing center. At present, the company's sequencing throughput is the second in the world, and the output of tumor gene data ranks in the forefront of the country. The business covers 300+ top three hospitals in more than 30 provinces.

Merck Sharp & Dohme LLC, part of Merck & Co., Inc., is a company headquartered in Kenilworth, NJ, that operates as a pharmaceutical company.

Beijing Qichensheng Biotechnology Co., Ltd., established on 2015-12-15, The scope of business includes engaging in biomedicine,Technology development of biological detection and treatment technology,Technical Services,technical consulting,technology transfer,Technical Training;Sales of chemical products,chemical reagent,Instrumentation,Ι class medical device;Technology Import and Export;Conference Services;Undertake exhibition and display activities.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

NCPC New Drug Research & Development Co. Ltd., a subsidiary of Province of Hebei, is a Chinese company located in Shijiazhuang. The firm manufactures and distributes medicines.

China State Institute of Pharmaceutical Industry is a company headquartered in Shanghai, China and ultimately controlled by the Government of China. The firm regulates pharmaceutical companies.

Henan Yukang Bioengineering Technology Co., Ltd., established on 2004-09-03, Business scope includes research and sales of bioengineering products;Biotechnology,electronic technology,New material research;Research on fine chemical products and technical services for bioengineering products,Achievement transfer,Technology Development Consulting(law,Prohibited by law,Not allowed to operate;subject to approval,Do not operate without approval).

Five3 Genomics, LLC offers cancer genome data processing services. The company provides genome processing services for researchers including alignment, mutational calling, rearrangement detection, and copy number estimation. It caters to research, biotech, and patient care sectors. Five3 Genomics, LLC is based in Santa Cruz, California.

Changzhou Tongshu Biological Technology Co., Ltd. is a company headquartered in China that operates medical clinical inspection centers.

Sichuan Academy of Chinese Medicine Sciences, a subsidiary of Province of Sichuan, is a company headquartered in China that manufactures medicinal chemicals.

Rizhao Tianyi Biomedical Technology Co., Ltd., established on 2007-08-24, Business scope includes general items:Production of Class I Medical Devices;Production of protective equipment for medical personnel(Ι class medical device);Sales of Class I Medical Devices;Sales of Class II Medical Devices;Sales of hygiene products and single-use medical products;Wholesale of protective equipment for medical staff;Retailing of protective equipment for healthcare workers;Engineering and Technology Research and Experimental Development;Intellectual Property Services;R&D and application of cell technology;Medical Research and Experimental Development;Medical equipment rental;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Production of hygiene products and single-use medical products;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Guangzhou Xiongji Bio-Information Technology Co., Ltd., established on 2019-05-16, Business scope includes technology research and development of biochemical products;Research and development of bio-based materials technology;Research and development of bio-based material polymerization technology;5GCommunication Technology Services;Information Technology Consulting Services;Information system integration service;electronics sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Computer System Services;software sales;software development;Artificial intelligence application software development;R&D and application of cell technology;